Clinical trials: Neoplasms, Ovarian
Ovarian Cysts
Laparoscopy-assisted Ovarian Cystectomy: NEW APPROCH
Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).
- Trial name
- NCT03370952
- Testing
- laproscopy, combined laproscopic and minilaparotomy ovarian cystectomy
- Where
- Egypt
- Volunteers
- 112 people
- Sponsor
- Cairo University
Ovarian Cancer, Endometrial Cancer
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
This study is a Single-center, open, single-arm and non-randomized clinical trial in China. The aim of this study is to evaluate the efficacy, safety, and tolerability of Arsenic trioxide for injection in patients with recurrent…
- Trial name
- NCT04489706
- Testing
- Arsenic trioxide for injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Ovarian Cancer Recurrent
Microtransplantation for Ovarian Cancer
In this study, we will apply micro transplantation to the field of recurrent and advanced ovarian cancer to study the efficacy and safety.
- Trial name
- NCT05095558
- Testing
- microtransplantation, HLA-mismatched donor peripheral stem cell infusion
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Polycystic Ovary Syndrome, Insulin Resistance
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
The aim of this study is to explore the microRNA profile in serum of women with Polycystic Ovary Syndrome and investigate the correlation between the microRNA profile and markers of metabolic syndrome.
- Trial name
- NCT03142633
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Holbaek Sygehus
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Polycystic Ovary Syndrome
Transcriptomic Profile of Adipose Tissue Following n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation
Adipose tissue is a central organ involved in mediating metabolic health, and so the investigation of treatments which improve adipose tissue function is warranted.
- Trial name
- NCT01195155
- Testing
- LC n-3 PUFA (fish oil) Supplement
- Where
- 2 sites in Ireland
- Volunteers
- 10 people
- Sponsor
- The Adelaide and Meath Hospital
Polycystic Ovary Syndrome
Use of Osteopathic Principles for Nonpharmacologic, Therapeutic Interventions in Women With Polycystic Ovary Syndrome
The overall goals of this project are to assess the efficacy of non-pharmacological, complementary therapies to improve outcomes in the treatment of women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT03383484
- Testing
- OMT, Yoga
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Diana Speelman, Ph.D.
Ovarian Cancer
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled
- Trial name
- NCT06188455
- Testing
- Fluzoparib Capsules, Apatinib Mesylate Tablets
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer, Fallopian Tube Cancer
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including Fallopian tube cancer and primary peritoneal cancer).
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- HITOMI (NCT03159572)
- Where
- Japan
- Volunteers
- 996 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Breast Cancer, Ovarian Cancer
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Conditions
- Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- BMS-247550 (NCT00005807)
- Testing
- BMS-247550
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Albert Einstein College of Medicine
Poly Cystic Ovary Syndrome, Overweight , Obesity
Physical Activity and Cardiometabolic Health in Women With or Without Polycystic Ovary Syndrome (SCOPAP)
The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight…
- Trial name
- SCOPAP (NCT07659392)
- Testing
- Physical activity
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Polycystic Ovary Syndrome
Could the Therapy With Inositol Affect the Cardiovascular Risk in PCOS Women? Results of a Randomized Clinical Trial
Polycystic ovary syndrome (PCOS) is associated with an increased cardiovascular risk. The aim of the study was to evaluate long-term effects of inositol on some cardiovascular risk factors in PCOS patients.
- Trial name
- NCT01574261
- Testing
- Inositol
- Where
- Italy
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back (recurrent), remains despite treatment (persistent), or is growing, spreading, or…
- Trial name
- NCT03602586
- Testing
- Epacadostat, Pembrolizumab
- Where
- 363 sites in United States, Puerto Rico
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Epithelial Ovarian Cancer
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer
Rationale Ovarian cancer is the 3rd most common gynecologic malignancy in Korea. The standard treatment is tumor debulking surgery with or without adjuvant chemotherapy.
- Trial name
- SABR-ROC (NCT05444270)
- Testing
- Standard salvage therapy, Standard salvage therapy + SABR
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Yonsei University
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovarian Neoplasms
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise therapy is of great importance.
- Trial name
- NCT05290961
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Gynecological Tumor, Ovarian Cancer
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced…
- Conditions
- Gynecological Tumor, Ovarian Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06007586
- Testing
- Aprepitant Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Breast Cancer, Ovarian Cancer
Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System
The study evaluates the level and molecular profiles of different CTC populations as markers for predicting the risk of developing hematogenous metastases and the effectiveness of treatment in patients with tumors of the female…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- CTCs (NCT04817501)
- Testing
- Taking 5 ml of venous blood at different time intervals, Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Cardiovascular Diseases
Reexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study
The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary…
- Trial name
- HER-CROWN (NCT05632601)
- Testing
- PET scan
- Where
- Canada
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation